The Benefic Effects of Cannabis on Patients with Multiple Sclerosis

Relating to recently conducted trials, cannabis can be considered an efficient cure for patients diagnosed with multiple sclerosis. While at first the symptomatic improvements experienced by patients with multiple sclerosis who have been given cannabinoid products were thought to be determined only by psychological factors, later research has revealed that cannabis actually reduces buff spasms and stiffness typical to multiple sclerosis victims. The benefic effects of cannabis on patients with multiple sclerosis have recently been confirmed by short-term and long-term manipulated medical studies. Buy CBD Post Workout

In 2003, a team of researchers from the Peninsula Medical School in Exeter, UK make general population the results of any series of short-term and long lasting studies on the results of cannabinoids among patients with multiple sclerosis. The previously conducted studies engaged the active participation of around 600 patients with advanced-stage multiple sclerosis. The participants were divided in two distinctive groups: the first group received cannabinoid compounds in equal dosage, while the second group received placebo medications over a period of 12-15 weeks. Right at the end of the experiment, virtually all patients who were administered cannabinoids experienced considerable symptomatic improvements, having less muscular pain and being confronted with more gentle muscular spasticity (less said muscular spasm). Unlike the group that received cannabinoid compounds over the complete length of the study, the control group (patients who received placebo medications) experienced no improvements in their overall condition.

In order to confirm the relevancy of the findings also to dispose of any doubts concerning the efficiency of cannabis in ameliorating the symptoms of multiple sclerosis, the review was later repeated. The ulterior study was performed over a period of 12 months, and engaged the participation of the identical subjects. However, this time the participants were divided into 3 distinctive groups rather than 2 as in the case of the prior experiment. The first group received pills of D9-tetrahydrocannabinol (THC) – the active component in cannabis, the other group received natural cannabis extracts, while the third group received placebo medications.

At the conclusion of the experiment, patients were carefully evaluated and analyzed by a team of physiotherapists and neurologists. The very best results were obtained among the patients belonging to the first study group, the vast majority of subjects who have received equal doses of THC experiencing considerable advancements in their symptoms. The patients in the second study group experienced moderate improvements in their symptoms, while the patients in the third group experienced no changes in their condition.